In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2- naphthyl}ethylidene)malononitrile

Neuroscience

Volumn 117, Issue 3, 2003, Pages 723-730

  Agdeppa, E D ^a   Kepe, V ^a   Petric A ^b   Satyamurthy, N ^a   Liu, J ^a   Huang, S C ^a   Small, G W ^a   Cole, G M ^a,c   Barrio, J R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anti aggregation; Competitive binding; Digital autoradiography; Fluorescence microscopy; Non steroidal anti inflammatory drugs; amyloid fibrils

Indexed keywords

2 [1 [6 [(2 FLUOROETHYL)(METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONONITRILE F 18; AMYLOID BETA PROTEIN; CONGO RED; DICLOFENAC; IBUPROFEN; MALONONITRILE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; THIOFLAVINE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; CASE REPORT; DRUG BINDING; DRUG DETERMINATION; DRUG POTENCY; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR DYNAMICS; MOLECULAR PROBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENILE PLAQUE;

EID: 0037475148     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00907-7     Document Type: Article

References (46)

1. Adams S.S., Bough R.G., Cliffe E.E., Lessel B., Mills R.F.N. Absorption, distribution and toxicity of ibuprofen. Toxicol Appl Pharmacol. 15:1969;310-330.
2. Adams S.S., Bresloff P., Mason C.G. Pharmacological differences between the optical isomers of ibuprofen Evidence for metabolic inversion of the (-)-isomer . J Pharm Pharmacol. 28:1976;256-257.
3. Agdeppa E.D., Kepe V., Kiziloglu Z.N., Petriĉ A., Zabjek A., Satyamurthy N., Cole G.M., Vinters H.V., Small G.W., Barrio J.R. FDDNP analogs as probes for plaques and tangles in Alzheimer's disease. J Nucl Med. 41:(suppl):2000;25P.
4. Agdeppa E.D., Kepe V., Liu J., Flores-Torres S., Satyamurthy N., Petriĉ A., Cole G.M., Small G.W., Huang S.-C., Barrio J.R. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease. J Neurosci. 21:2001;1-5. RC189.
5. Agdeppa E.D., Kepe V., Petriĉ A., Liu J., Satyamurthy N., Shoghi-Jadid K., Small G.W., Huang S.-C., Barrio J.R. Torsionally modified FDDNP analogs have picomolar binding affinity to plaques in Alzheimer's disease. J Nucl Med. 43:((suppl):):2002;166P.
6. Agdeppa E.D., Kepe V., Shoghi-Jadid K., Satyamurthy N., Small G.W., Petriĉ A., Vinters H.V., Huang S.-C., Barrio J.R. In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer's disease patient a case study . J Nucl Med. 42:((suppl):):2001;65P.
7. Aisen P.S., Davis K.L., Berg J.D., Schafer K., Campbell K., Thomas R.G., Weiner M.F., Farlow M.R., Sano M., Grundman M., Thal L.J. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Dis Cooperative Study Neurol. 54:2000;588-593.
8. Anthony J.C., Breitner J.C., Zandi P.P., Meyer M.R., Jurasova I., Norton M.C., Stone S.V. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists the Cache County Study . Neurology. 54:2000;2066-2071.
9. Bancroft J.D., Stevens A. Theory and practice of histological techniques. 1990;Churchill Livingstone, New York.
10. Bannwarth B., Lapicque F., Pehourcq F., Gillet P., Schaeverbeke T., Laborde C., Dehais J., Gaucher A., Netter P. Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. Br J Clin Pharmacol. 40:1995;266-269.
11. 18F]fluoroethyl)spiperone in vivo biochemical and kinetic characterization in rodents, nonhuman primates, and humans . J Cereb Blood Flow Metab. 9:1989;830-839.
12. Bradley J.D., Rudy A.C., Katz B.P., Ryan S.I., Kalasinski L.A., Brater D.C., Hall S.D., Brandt K.D. Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis. J Rheumatol. 19:1992;130-134.
13. Breitner J.C.S., Welsh K.A., Helms M.J., Gaskell P.C., Gau B.A., Roses A.D., Pericak-Vance M.A., Saunders A.M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 16:1995;523-530.
14. Breteler M.M.B., in t' Veld B., Hofman A., Stricker B.H.C. Aβ-42 peptide lowering NSAIDs and Alzheimer's disease. Neurobiol Aging. 23:((suppl):):2002;S286.
15. Broe G.A., Grayson D.A., Creasey H.M., Waite L.M., Casey B.J., Bennett H.P., Brooks W.S., Halliday G.M. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol. 57:2000;1586-1591.
16. Caldwell J., Winter S.M., Hutt A.J. The pharmacological and toxicological significance of the stereochemistry of drug disposition. Xenobiotica. 18:((suppl):):1988;59-70.
17. Dean P.M. Molecular foundations of drug-receptor interaction. 1987;Cambridge University Press, Cambridge.
18. Engler H., Blomqvist G., Bergstrom M., Estrada S., Sandell J., Antoni G., Langstrom B., Barletta J., Klunk W., Debnath M., Holt D., Wang Y., Huang G.-F., Mathis C. First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiol Aging. (23(suppl):):2002;S429.
19. Findeis M.A. Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization. Biochim Biophys Acta. 1502:2000;76-84.
20. Halliday G., Robinson S.R., Shepherd C., Kril J. Alzheimer's disease and inflammation a review of cellular and therapeutic mechanisms . Clin Exp Pharmacol Physiol. 27:2000;1-8.
21. in t' Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., Stricker B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 345:2001;1515-1521.
22. Jacobson A., Petriĉ A., Hogenkamp D., Sinur A., Barrio J.R. 1,1-dicyano-2-(6-dimethylaminonaphthalen-2-yl)propene (DDNP) a solvent polarity and viscosity sensitive fluorophore for fluorescence microscopy . J Am Chem Soc. 118:1996;5572-5579.
23. Klunk W.E., Jacob R.F., Mason R.P. Quantifying amyloid β-peptide (Aβ) aggregation using the Congo red-Aβ (CR-Aβ) spectrophotometric assay. Anal Biochem. 266:1999;66-76.
24. Klunk W.E., Wang Y., Huang G.-f, Debnath M.L., Holt D.P., Mathis C.A. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 69:2001;1471-1484.
25. Kung H.F., Lee C.-W., Zhuang Z.-P., Kung M.-P., Hou C., Plossl K. Novel stilbenes as probes for amyloid plaques. J Am Chem Soc. 123:2001;12740-12741.
26. Lansbury P.T. A reductionist view of Alzheimer's disease. Acc Chem Res. 29:1996;317-321.
27. LeVine H. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides detection of amyloid aggregation in solution . Protein Sci. 2:1993;404-410.
28. 3H)N-n-propylnorapomorphine . J Neural Transm. 68:1987;15-23.
29. Mayer J.M. Stereoselective metabolism of anti-inflammatory 2-arylpropionates. Acta Pharm Nord. 2:1990;197-216.
30. McEvoy G.K. 2002;Authority of the Board of Directors of the American Society of Hospital Pharmacists, Bethesda.
31. McGeer P.L., McGeer E.G. The inflammatory response system of brain implications for therapy of Alzheimer and other neurodegenerative diseases . Brain Res Brain Res Rev. 21:1995;195-218.
32. Micheli L., Fiaschi A.I., Cerretani D., Giorgi G. Non-steroidal anti-inflammatory drugs (NSAIDs) affect the glutathione (GSH) levels in the brain. Ann Ist Super Sanita. 29:1993;387-390.
33. Parrott K.A., Christensen J.M. Influence of cimetidine on the disposition of ibuprofen in the rat. Res Commun Chem Pathol Pharmacol. 43:1984;369-380.
34. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P., Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
35. Runkel R., Chaplin M., Boost G., Segre E., Forchielli E. Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J Pharm Sci. 61:1972;703-708.
36. Scharf S., Mander A., Ugoni A., Vajda F., Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 53:1999;197-201.
37. Schnell S.A., Staines W.A., Wessendorf M.W. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem. 47:1999;719-730.
38. Selkoe D.J. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol. 10:1994;373-403.
39. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petriĉ A., Huang S.C., Barrio J.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Geriatr Psychiatry. 10:2002;24-35.
40. Sorenson J.A., Phelps M.E. Physics in nuclear medicine. 1987;Grune and Stratton, Orlando.
41. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632.
42. Teplow D.B. Structural and kinetic features of amyloid β-protein fibrillogenesis. Amyloid. 5:1998;121-142.
43. Thomas T., Nadackal T.G., Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation. Neuroreport. 12:2001;3263-3267.
44. Van Gool W.A., Weinstein H.C., Scheltens P., Walstra G.J., Scheltens P.K. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease an 18-month randomised, double-blind, placebo-controlled study . Lancet. 358:2001;455-460.
45. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., Koo E.H. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature. 414:2001;212-216.
46. 2 receptor antagonists the Cache County Study . Neurology. 59:2002;880-886.